Can diet and exercise slow prostate Cancer's return after surgery?

NCT ID NCT03999151

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study tests whether different combinations of diet and exercise support tools—like educational materials, text messaging, and coaching—can improve outcomes for men with prostate cancer who choose surgery. Researchers will track PSA recurrence and quality of life over time. The goal is to see if lifestyle changes can help delay or prevent cancer from coming back.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a behavioral program combining educational materials, text messaging, and coaching on diet and exercise
What this could lead to
If successful, this could show that lifestyle changes help delay prostate cancer recurrence after surgery, offering a non-drug way to improve outcomes.
What could go wrong
This is a relatively small trial testing behavioral tools, not a drug, so the effects may be modest. Results may not apply to all men with prostate cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

204 people

The number who actually took part.

Started

May 2018

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age \>=18 years 2. Diagnosed with non-metastatic prostate cancer and choose radical prostatectomy (RP) as primary treatment. 3. Able to speak and read English 4. Regular access to the Internet (via a computer, tablet, or phone) and text messaging capabilities on the phone 5. Ability to understand a written informed consent document, and the willingness to sign it Exclusion Criteria: 1. Cannot have neoadjuvant radiation or hormone therapy planned at time of enrollment (if enrolling \>4 weeks prior to RP). 2. Men who have contraindications to exercise based the American College of Sports Medicine 2016 Exercise pre-participation screening criteria (https://www.ncbi.nlm.nih.gov/pubmed/26473759), and who do not receive a physician clearance to participate in the moderate to vigorous intensity physical activity with one or more of the following self-reported conditions: 1. Heart attack 2. Heart surgery, cardiac catheterization, or coronary angioplasty 3. Pacemaker/implantable cardiac defibrillator/rhythm disturbance 4. Heart valve disease 5. Heart failure 6. Heart transplantation 7. Congenital heart disease 8. Diabetes 9. Kidney (renal) disease 10. Chest discomfort with exertion 11. Unreasonable breathlessness 12. Dizziness, fainting, or blackouts 13. Ankle swelling 14. Unpleasant awareness of forceful, rapid or irregular heart rate 15. Burning or cramping sensations in your lower legs when walking short distance 3. Men already meeting aerobic AND resistance exercise recommendations. To be eligible, must not meet at least one of the following: (1) 150 minutes per week of planned moderate aerobic exercise or 75 minutes per week of planned vigorous aerobic exercise or combination;(2) Two or more days per week of resistance exercise; (3) Eight or more resistance exercises per session 4. Men who are already meeting all of the 7 prostate-specific dietary recommendations

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Motor Activity prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of California, San Francisco (UCSF)

    San Francisco, California, 94143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.